Commonly prescribed beta 2 adrenergic agonist drugs for the treatment of asthma in pregnant women as well as pre-term labor may increase the incidence of autism-spectrum disorders, psychiatric pathology, cognitive problems and poor school performance in their children, according to a new study published in the December 2009 issue of the American Journal of Obstetrics [...]

In a new study, researchers report that a class of heart medications called beta-blockers can have a helpful, or harmful, effect on the heart, depending on their molecular activity.
The study, which appears in the journal Circulation Research, found that beta-blockers that target both the alpha- and beta-receptors on the heart muscle offer the most benefit [...]

Sciele Pharma, Inc., a Shionogi Company, today announced that Addrenex Pharmaceuticals, Inc. has initiated its Phase II clinical trial with ADX415 for the treatment of hypertension. This is a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study that will involve 80 patients. ADX415 is a novel, patented, centrally acting, alpha-adrenergic receptor agonist, specific to Alpha-2 receptors.